CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Ad5 CEA Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01147965
NCT01147965Phase 2Completed
CompareCT.gov

A Phase I/II Study of Active Immunotherapy With Ad5 [E1-,E2b-]-CEA(6D) Vaccine in Patients With Advanced or Metastatic Malignancies Expressing CEA

NantCell, Inc.·interventional·Posted Jun 22, 2010·Updated Nov 25, 2025

In Brief

A Phase 2 clinical trial evaluating Ad5 CEA Vaccine for Colorectal Cancer and 3 related conditions. Completed, enrolled 43 participants across 2 sites.

Detailed Summary

The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 \[E1-, E2b-\]-CEA(6D)or ETBX-011 and is made by Etubics. This vaccine is based on a virus called an adenovirus but it has been changed to express the protein CEA that is found on some cancer cells. Therefore, the vaccine can tell the immune system to attack cancer cells which make CEA. The investigators are trying to determine whether giving this virus is safe and whether this causes a strong immune system attack on the cancer. ETBX-011 is an investigational drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Lung Cancer, Breast Cancer, Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 22, 2010
Enrollment StartJul 16, 2010
Primary CompletionMay 31, 2017
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 16.0 years ago

Interventions

Ad5 CEA Vaccinebiological

Ad5 \[E1-, E2b-\]-CEA(6D) Vector Vaccine